New CryoDuo Expands Access to Powerful Minimally Invasive Treatment for Pets
Baltimore, MD, September 24, 2026 - Kubanda Cryotherapy, a leading developer of novel cryotherapy solutions, has introduced CryoDuo, a new minimally invasive treatment for lumps, bumps, and tumors in pets. The point-of-care system features dual-treatment functionality, making it the first and only device of its kind capable of supporting both topical and subcutaneous tumor applications in the veterinary market.
Veterinarians are increasingly seeking treatment options that prioritize patient outcomes, reduce the need for anesthesia, shorten recovery times, and expand the range of cases they can treat in-house without referring out. CryoDuo marks a breakthrough advancement in veterinary cryotherapy technology to address this need, providing a versatile, powerful solution for topical and subcutaneous masses alike. From mobile clinics to specialty centers to general practices, veterinarians across the world now have access to cutting-edge, precision tumor treatment - wherever the point-of-care may be.
“I founded Kubanda based on the core belief that cutting-edge technology and treatment should not be limited based on income or access,” said Bailey Surtees, Founder and CEO of Kubanda Cryotherapy. “I get to see that mission in action every day now - whether it’s a family dog who had no other options that's back to running around like a puppy, or a cat that now cuddles with his pet parent for the first time in years - our vision is shaping what’s possible for the next generation of care.”
To learn more about the CryoDuo, visit kubandacryotherapy.com/products.
About Kubanda Cryotherapy:
Kubanda Cryotherapy is the first minimally invasive point-of-care treatment for lumps, bumps, and tumors in pets. Their unique cryotherapy solution allows for effective treatment of both topical and subcutaneous lesions - at half the cost of surgery. This product launch comes on the tail of a successful $1.7M seed round closed in 2025, marking over $5M raised to date, including over $2M in research awards.